STRUCTURED ABSTRACT
Background Biomarkers are needed to monitor disease progression, target engagement and efficacy in Huntington’s disease (HD). Cerebrospinal fluid (CSF) is an ideal medium to research such biomarkers due to its proximity to the brain.
Objectives To investigate the safety and feasibility of research lumbar punctures (LP) in HD.
Methods HDClarity (NCT02855476) is an ongoing international biofluid collection initiative built on the Enroll-HD platform, where clinical assessments are recorded. It aims to recruit 1,200 participants. Biosamples are collected following an overnight fast: blood via venipuncture and CSF via LP. Participants are healthy controls and HD gene expansion carriers across the disease spectrum. We report on monitored data from February 2016 to September 2019.
Results Of 448 participants screened, 398 underwent at least 1 sampling visit, of which 98.24% were successful (i.e. CSF was collected), amounting to 10,610mL of CSF and 8,200mL of plasma. In the total 572 sampling visits, adverse events were reported in 24.13%, and headaches of any kind and post-LP headaches in 14.86% and 12.24%, respectively. Frequencies were less in manifest HD; gender, age, body mass index and disease burden score were not associated with the occurrence of the events in gene expansion carriers. Headaches and back pain were the most frequent adverse events.
Conclusions HDClarity is the largest CSF collection initiative to support scientific research into HD and is now established as a leading resource for HD research. Our data confirm that research LP in HD are feasible and acceptable to the community, and have a manageable safety profile.
Competing Interest Statement
FBR, GO, KS and EJW are University College London employees. FBR has provided consultancy services to GLG and F. Hoffmann-La Roche Ltd. EJW reports grants from Medical Research Council, CHDI Foundation, and F. Hoffmann-La Roche Ltd during the conduct of the study; personal fees from Hoffman La Roche Ltd, Triplet Therapeutics, PTC Therapeutics, Shire Therapeutics, Wave Life Sciences, Mitoconix, Takeda, Loqus23. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London. University College London Hospitals NHS Foundation Trust, has received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, Pfizer and Teva Pharmaceuticals. SS, EP, AGE, DK, SL, JLev and CS derive their compensation from CHDI Management/CHDI Foundation. JT is employed by the Enroll-HD platform. BRL reports related research grant funding from Canadian Institutes of Health Research, CHDI Foundation, Weston Foundation, the Huntington Society of Canada, uniQure, Teva, and Roche during the conduct of the study; Paid scientific consultancies from Ionis Pharmaceuticals, Roche, Triplet Therapeutics, PTC Therapeutics, Novartis, Teva, Mitoconix, Takeda, and uniQure; and the Centre for HD at UBC Hospital has received funding to conduct clinical trials in HD from CHDI, Ionis Pharmaceuticals, Roche, Vaccinex, and Teva Pharmaceuticals via the HSG. MG has provided consultancy services to F. Hoffmann-La Roche Ltd, Novartis, PTC Therapeutics and CHDI Foundation. Research support from Hoffmann-La Roche, Ltd, Wave Life Sciences, Triplet Therapeutics, Neurocrine Biosciences and CHDI Foundation Inc. JB has served on the Scientific Advisory Board for WAVE and has provided consultancy services to F. Hoffman-La Roche Ltd. JLew is an employee of the Ulm University medical center. JLew received grants from the Bundesministerium for Bildung und Forschung (BMBF, German ministry for education and research) and the European Huntington's disease network (EHDN) during the conduct of the study. JLew is member of the extended board of the Deutsche Gesellschaft für Liquordiagnostik und klinische Neurochemie (German society for cerebrospinal fluid diagnostics and clinical neurochemistry), has received funds as compensation for conducting clinical trials for UCB Biosciences, Marinus Pharmaceutical and CHDI, received speakers honoraria by TEVA Pharmaceuticals, CHDI and the Movement Disorders Society. CS has received consultancy honoraria from from vTv Therapeutics, Pinteon Therapeutics, Kyowa Kirin, Pfizer, The Green Valley Pharmaceuticals, and Neuraly.
Clinical Trial
NCT02855476
Clinical Protocols
http://hdclarity.net/study-information/
Funding Statement
HDClarity is funded and supported by CHDI Foundation, Inc., a not-for-profit organization dedicated to finding treatments for Huntington's disease. EJW was supported by CHDI Foundation Inc. and Medical Research Council UK (Clinician Scientist Fellowship MR/M008592/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
HDClarity is performed in accordance with the principles of the Declaration of Helsinki, and the International Conference on Harmonization and the World Health Organization Good Clinical Practice standards. All participating sites sought appropriate ethical approval in accordance with each specific country legislation (more details including Ethics Committees / Institutional Review Boards decisions below). All reported participants gave informed consent prior to undertaking study procedures. Ethics Committees / Institutional Review Boards decisions: Center Movement Disorders, CA: -Approval by Western Institutional Review Board (STUDY NUM: 1169046) University British Columbia, CA: -Approval by Clinical Research Ethics Board, University of British Columbia (UBC CREB NUMBER: H16-02183) George Huntington Institute, DE: -Approval by Ethik Kommission der Arztekammer Westfalen-Lippe und der Westfalischen Wilhelms-Universitat (Unser Aktenzeichen: 2017-130-b-S) St Josef And Elisabeth Hospital, DE: -Approval by Ethik-Kommission der Medizinischen Fakultat der Ruhr Universitat Bochum (Reg.-Nr.: 17-5997) University Hospital Erlangen, DE: -Approval by Ethik-Kommission der Friedrich-Alexander Universitat (Antrag Nr.: 285_17 Bc) University Hospital Ulm, DE: -Approval by Ethikkommission der Universitat Ulm (Antrag Nr. 286/16) BirmSolNHSFounTrust, UK: -UK-wide approval by London - Camberwell St Giles Research Ethics Committee (REC reference: 16/LO/1878) -Local approval by Birmingham and Solihull Mental Health NHS Foundation Trust (IRAS 185506) GreatGlasgowHealthBoard, UK: -UK-wide approval by London - Camberwell St Giles Research Ethics Committee (REC reference: 16/LO/1878) -Local approval by Greater Glasgow and Clyde Health Board (R&D reference: GN16NE605) LeedsTeachHospTrust, UK: -UK-wide approval by London - Camberwell St Giles Research Ethics Committee (REC reference: 16/LO/1878) -Local approval by Leeds Teaching Hospitals NHS Trust (R&I No: CG16/81309) StGeorgeHealthTrust, UK: -UK-wide approval by London - Camberwell St Giles Research Ethics Committee (REC reference: 16/LO/1878) -Local approval by St George's University Hospitals NHS Foundation Trust (R&D number 17.0054) University Cambridge, UK: -UK-wide approval by London - Camberwell St Giles Research Ethics Committee (REC reference: 16/LO/1878) -Local approval by Research and Development Department, Cambridge University Hospitals NHS Foundation Trust (R&D ref: A094293) University College London, UK: -UK-wide approval by London - Camberwell St Giles Research Ethics Committee (REC reference: 16/LO/1878) -Local approval by London - Camberwell St Giles Research Ethics Committee (REC reference: 16/LO/1917) JohnsHopkinsUniv, US: -Approval by Office of Human Subject Research Institutional Review Boards, Johns Hopkins (Number: IRB00104965) WakeForestUniv, US: -Approval by Wake Forest University School of Medicine Institutional Review Board (IRB Number: IRB00040219) UnivTexasHlthCntrHous, US: -Approval by Committee for the Protection of Human Subjects, UTHealth, the University of Texas (HSC-MS-17-0731)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
